Real-world lenvatinib use in metastatic thyroid cancer: early dose intensity and side effect profile in an Australian centre
This real-world analysis demonstrates difficulties in maintaining early lenvatinib dose intensity, with frequent TRAEs. Greater emphasis on supportive care is needed to maximise early dose intensity and efficacy.
Authors
- Matti L. Gild (ORCID: https://orcid.org/0000-0002-6670-2254)
- Shejil Kumar (ORCID: https://orcid.org/0000-0002-1242-2476)
- Anthony Robert Glover (ORCID: https://orcid.org/0000-0003-0762-0977)
- Roderick John Clifton-Bligh (ORCID: https://orcid.org/0000-0002-1545-0368)
- Lyndal Tacon
- Tony Lian (ORCID: https://orcid.org/0000-0003-4936-0106)
- Venessa Tsang
- Bruce G. Robinson
- Monica Majumder (ORCID: https://orcid.org/0000-0002-9796-4687)
- Meredith Oatley
Institutions
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Royal North Shore Hospital (AU)
- UNSW Sydney (AU)
- St Vincent's Clinic (AU)
- The Kinghorn Cancer Centre (AU)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1530/eo-24-0062
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00